NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameNewcelX AG
-
Registration countrySwitzerland
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









